Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Phase 1/2 × vandetanib × Sarcoma × Clear all

Phase

Phase 2 2 Phase 1 2 Phase 1/2 1

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Sarcoma 1 Head & Neck 1 Gynecologic 1 Genitourinary 1 Endocrine 1 CNS 1

Conditions

Gliosarcoma 1 Glioblastoma 1

Interventions

Temozolomide 32 Radiotherapy 31 Cyclophosphamide 16 Irinotecan 15 Gemcitabine 14 Doxorubicin 14 pembrolizumab 13 Imatinib Mesylate 10 Radiation 9 Nivolumab 9 Ifosfamide 9 Docetaxel 9 Vincristine 8 Filgrastim 8 Carboplatin 8 Bevacizumab 8 Sirolimus 7 Everolimus 7 Etoposide 6 pazopanib 5 fludarabine phosphate 5 atezolizumab 5 Vorinostat 5 Specimen Handling 5 Peripheral Blood Stem Cell Transplantation 5 PM 01183 5 Erlotinib Hydrochloride 5 Carmustine 5 Biopsy 5 temsirolimus 4

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT00441142 2019-03-05

Zactima

Dana-Farber Cancer Institute

Phase 1/2 Completed

119 enrolled 15 charts

Glioblastoma, Gliosarcoma

Data powered by HemOnc (CC BY 4.0) Colophon ⚡